Interferon therapy in LKM-1 positive patients with chronic hepatitis C: follow-up by a quantitative radioligand assay for CYP2D6 antibody detection.

doi:10.1016/s0168-8278(98)80344-9

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Interferon therapy in LKM-1 positive patients with chronic hepatitis C: follow-up by a quantitative radioligand assay for CYP2D6 antibody detection.

Journal of hepatology - 1 Jun 1998

Duclos-Vallée J C, Nishioka M, Hosomi N, Arima K, Leclercq A, Bach J F, Yamamoto A M

Abstract excerpt

BACKGROUND/AIMS: Liver/kidney microsomal type 1 (LKM-1) antibodies described by indirect immunofluorescence using frozen sections of kidney, stomach and rat liver define a group of patients with type 2 autoimmune hepatitis. Sera react with a non-glycosylated 50-kD protein of the endoplasmic retic...

Topics

Adult
Alanine Transaminase
Animals
Antiviral Agents
Autoantibodies
Cytochrome P-450 CYP2D6
Female
Fluorescent Antibody Technique, Indirect
Follow-Up Studies
Genotype
HLA-DR Antigens
Hepacivirus
Hepatitis C, Chronic
Histocompatibility Antigens Class I
Humans
Interferons
Male
Middle Aged

Source

Open in PubMed

Identifiers

PMID: 9672171
DOI: 10.1016/s0168-8278(98)80344-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026. Prepared record publication-9672171-2026-08-30.1. Manifest publication-graph-cohort-2026-08-30.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics